Transcriptional Addiction in Cancer

[1]  Lluis Montoliu,et al.  Genome Editing , 2018, Advances in Experimental Medicine and Biology.

[2]  J. Wysocka,et al.  Ever-Changing Landscapes: Transcriptional Enhancers in Development and Evolution , 2016, Cell.

[3]  Daniel S. Day,et al.  Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control , 2016, Cell.

[4]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[5]  Yonatan Stelzer,et al.  Editing DNA Methylation in the Mammalian Genome , 2016, Cell.

[6]  R. Kohli,et al.  The expanding scope and impact of epigenetic cytosine modifications. , 2016, Current opinion in chemical biology.

[7]  J. Taipale,et al.  The role of enhancers in cancer , 2016, Nature Reviews Cancer.

[8]  N. Hannett,et al.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. , 2016, Nature chemical biology.

[9]  L. Pennacchio,et al.  Genetic dissection of the α-globin super-enhancer in vivo , 2016, Nature Genetics.

[10]  Mark W. Youngblood,et al.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas , 2016, Nature Genetics.

[11]  Pedro P. Rocha,et al.  Identification of multi-loci hubs from 4C-seq demonstrates the functional importance of simultaneous interactions , 2016, Nucleic acids research.

[12]  L. Hennighausen,et al.  Hierarchy within the mammary STAT5-driven Wap super-enhancer , 2016, Nature Genetics.

[13]  A. Shilatifard,et al.  Epigenetic balance of gene expression by Polycomb and COMPASS families , 2016, Science.

[14]  Scott B. Dewell,et al.  Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. , 2016, Molecular cell.

[15]  G. Pelosi,et al.  Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. , 2016, Cancer discovery.

[16]  Davide Cittaro,et al.  Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing , 2016, Cell.

[17]  Jae-seok Roe,et al.  BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. , 2016, Cell reports.

[18]  Rodolfo Ghirlando,et al.  CTCF: making the right connections , 2016, Genes & development.

[19]  M. Rosenfeld,et al.  Enhancers as non-coding RNA transcription units: recent insights and future perspectives , 2016, Nature Reviews Genetics.

[20]  M. Cole.  Faculty Opinions recommendation of DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. , 2016 .

[21]  Sigal Shachar,et al.  3D Chromosome Regulatory Landscape of Human Pluripotent Cells. , 2016, Cell stem cell.

[22]  Roland Eils,et al.  Active medulloblastoma enhancers reveal subgroup-specific cellular origins , 2016, Nature.

[23]  Jennifer A. Doudna,et al.  Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering , 2016, Cell.

[24]  Shawn M. Gillespie,et al.  An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma , 2016, Nature Genetics.

[25]  Marcin Imielinski,et al.  Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers , 2015, Nature Genetics.

[26]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[27]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[28]  Daniel S. Day,et al.  Activation of proto-oncogenes by disruption of chromosome neighborhoods , 2015, Science.

[29]  Tae-Kyung Kim,et al.  Stimulus-specific combinatorial functionality of neuronal c-fos enhancers , 2015, Nature Neuroscience.

[30]  D. Zheng,et al.  ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas , 2015, eLife.

[31]  S. Armstrong,et al.  Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. , 2015, Molecular cell.

[32]  A. Jolma,et al.  DNA-dependent formation of transcription factor pairs alters their binding specificity , 2015, Nature.

[33]  N. Hannett,et al.  Transcription factor trapping by RNA in gene regulatory elements , 2015, Science.

[34]  Robert G. Ramsay,et al.  Directly targeting transcriptional dysregulation in cancer , 2015, Nature Reviews Cancer.

[35]  Sally Temple,et al.  A Systematic Approach to Identify Candidate Transcription Factors that Control Cell Identity , 2015, Stem cell reports.

[36]  Christopher J. Ott,et al.  Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis , 2015, The Journal of experimental medicine.

[37]  S. Armstrong,et al.  Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML , 2015, Nature.

[38]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[39]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[40]  R. Young,et al.  CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer , 2015, Cell.

[41]  C. Vakoc,et al.  Targeting Transcription Factors in Cancer. , 2015, Trends in cancer.

[42]  B. Weir,et al.  Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma , 2015, Oncotarget.

[43]  Scott A Armstrong,et al.  Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. , 2015, Experimental hematology.

[44]  Kevin R. Shieh,et al.  Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. , 2015, Cell Reports.

[45]  Niko Välimäki,et al.  CTCF/cohesin-binding sites are frequently mutated in cancer , 2015, Nature Genetics.

[46]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[47]  G. Crabtree,et al.  Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics , 2015, Science Advances.

[48]  Alexander J. Federation,et al.  RNA Exosome-Regulated Long Non-Coding RNA Transcription Controls Super-Enhancer Activity , 2015, Cell.

[49]  Charles Y. Lin,et al.  Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. , 2015, Molecular cell.

[50]  John T. Lis,et al.  Getting up to speed with transcription elongation by RNA polymerase II , 2015, Nature Reviews Molecular Cell Biology.

[51]  Dylan J. Taatjes,et al.  The Mediator complex: a central integrator of transcription , 2015, Nature Reviews Molecular Cell Biology.

[52]  W. Sellers,et al.  Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure , 2015, EMBO reports.

[53]  Nathan C. Sheffield,et al.  Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1 , 2015, Cell reports.

[54]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[55]  R. Evans,et al.  Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs , 2015, Proceedings of the National Academy of Sciences.

[56]  Yan Liu,et al.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. , 2014, Cancer cell.

[57]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[58]  J. Schug,et al.  Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia , 2014, Proceedings of the National Academy of Sciences.

[59]  R. Young,et al.  An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.

[60]  Tony Kouzarides,et al.  Histone core modifications regulating nucleosome structure and dynamics , 2014, Nature Reviews Molecular Cell Biology.

[61]  Bandana Sharma,et al.  CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer , 2014, Cell.

[62]  Andrew L. Kung,et al.  NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. , 2014, Molecular cell.

[63]  Jill M Dowen,et al.  Control of Cell Identity Genes Occurs in Insulated Neighborhoods in Mammalian Chromosomes , 2014, Cell.

[64]  Gary D Bader,et al.  Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.

[65]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[66]  B. Ren,et al.  The 3D genome in transcriptional regulation and pluripotency. , 2014, Cell stem cell.

[67]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[68]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[69]  Britta A. M. Bouwman,et al.  A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia , 2014, Cell.

[70]  Robert Tjian,et al.  Looping Back to Leap Forward: Transcription Enters a New Era , 2014, Cell.

[71]  Deqing Hu,et al.  Enhancer malfunction in cancer. , 2014, Molecular cell.

[72]  G. Morgan,et al.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.

[73]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[74]  J. Keith Joung,et al.  Interactome Maps of Mouse Gene Regulatory Domains Reveal Basic Principles of Transcriptional Regulation , 2013, Cell.

[75]  Ming Yu,et al.  Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation , 2013, Genes & development.

[76]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[77]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[78]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[79]  P. A. Futreal,et al.  Emerging patterns of somatic mutations in cancer , 2013, Nature Reviews Genetics.

[80]  Dirk Eick,et al.  The RNA polymerase II carboxy-terminal domain (CTD) code. , 2013, Chemical reviews.

[81]  Robert A Copeland,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[82]  A. Gnirke,et al.  Charting a dynamic DNA methylation landscape of the human genome , 2013, Nature.

[83]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[84]  Jennifer E. Phillips-Cremins,et al.  Chromatin insulators: linking genome organization to cellular function. , 2013, Molecular cell.

[85]  Rudolf Jaenisch,et al.  Mechanisms and models of somatic cell reprogramming , 2013, Nature Reviews Genetics.

[86]  R. Pearson,et al.  Dysregulation of the basal RNA polymerase transcription apparatus in cancer , 2013, Nature Reviews Cancer.

[87]  F. Lienert,et al.  Methylation-Dependent and -Independent Genomic Targeting Principles of the MBD Protein Family , 2013, Cell.

[88]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[89]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[90]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[91]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[92]  S. Armstrong,et al.  Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. , 2013, Blood.

[93]  Howard Y. Chang,et al.  Long Noncoding RNAs: Cellular Address Codes in Development and Disease , 2013, Cell.

[94]  J. Dekker,et al.  The hierarchy of the 3D genome. , 2013, Molecular cell.

[95]  R. Young,et al.  Transcriptional Regulation and Its Misregulation in Disease , 2013, Cell.

[96]  G. Evan,et al.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. , 2013, Genes & development.

[97]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[98]  R. Shiekhattar,et al.  Activating RNAs associate with Mediator to enhance chromatin architecture and transcription , 2013, Nature.

[99]  Albert E. Almada,et al.  Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells , 2013, Proceedings of the National Academy of Sciences.

[100]  N. Sodir,et al.  The Myc world within reach. , 2013, Methods in molecular biology.

[101]  Samantha A. Morris,et al.  A blueprint for engineering cell fate: current technologies to reprogram cell identity , 2013, Cell Research.

[102]  N. Heintz,et al.  MeCP2 binds to 5hmc enriched within active genes and accessible chromatin in the nervous system , 2012, Cell.

[103]  R. Mann,et al.  Disentangling the many layers of eukaryotic transcriptional regulation. , 2012, Annual review of genetics.

[104]  Thomas Vierbuchen,et al.  Molecular roadblocks for cellular reprogramming. , 2012, Molecular cell.

[105]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[106]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[107]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[108]  I. Sancho-Martinez,et al.  Lineage conversion methodologies meet the reprogramming toolbox , 2012, Nature Cell Biology.

[109]  E. Furlong,et al.  Transcription factors: from enhancer binding to developmental control , 2012, Nature Reviews Genetics.

[110]  Richard A Young,et al.  Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. , 2012, Cancer cell.

[111]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[112]  S. Yamanaka.  Induced pluripotent stem cells: past, present, and future. , 2012, Cell stem cell.

[113]  W. Tansey,et al.  Ubiquitin and proteasomes in transcription. , 2012, Annual review of biochemistry.

[114]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[115]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[116]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[117]  L. Aaltonen,et al.  MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas , 2011, Science.

[118]  David A. Orlando,et al.  Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-β Signaling , 2011, Cell.

[119]  George Q. Daley,et al.  Lineage Regulators Direct BMP and Wnt Pathways to Cell-Specific Programs during Differentiation and Regeneration , 2011, Cell.

[120]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[121]  V. Corces,et al.  Enhancer function: new insights into the regulation of tissue-specific gene expression , 2011, Nature Reviews Genetics.

[122]  P. Kaiser,et al.  Ubiquitin and transcription: The SCF/Met4 pathway, a (protein-) complex issue. , 2011, Transcription.

[123]  Mark Groudine,et al.  Functional and Mechanistic Diversity of Distal Transcription Enhancers , 2011, Cell.

[124]  David Lane,et al.  p53 Research: the past thirty years and the next thirty years. , 2010, Cold Spring Harbor perspectives in biology.

[125]  C. Pui,et al.  Glucocorticoid use in acute lymphoblastic leukaemia. , 2010, The Lancet. Oncology.

[126]  Sohail Malik,et al.  The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation , 2010, Nature Reviews Genetics.

[127]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[128]  Edwin Smith,et al.  The Language of Histone Crosstalk , 2010, Cell.

[129]  David A. Orlando,et al.  Mediator and Cohesin Connect Gene Expression and Chromatin Architecture , 2010, Nature.

[130]  G. Kreiman,et al.  Widespread transcription at neuronal activity-regulated enhancers , 2010, Nature.

[131]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[132]  Christopher B. Burge,et al.  c-Myc Regulates Transcriptional Pause Release , 2010, Cell.

[133]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[134]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2010, Nature.

[135]  T. Enver,et al.  Forcing cells to change lineages , 2009, Nature.

[136]  Danny Reinberg,et al.  Histones: annotating chromatin. , 2009, Annual review of genetics.

[137]  Sho Fujisawa,et al.  Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways , 2009, Cell.

[138]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[139]  William R Sellers,et al.  Linking somatic genetic alterations in cancer to therapeutics. , 2009, Current opinion in cell biology.

[140]  Juan M. Vaquerizas,et al.  A census of human transcription factors: function, expression and evolution , 2009, Nature Reviews Genetics.

[141]  Richard A Young,et al.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.

[142]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[143]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[144]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[145]  T. Mahmoudi,et al.  Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription , 2007, Proceedings of the National Academy of Sciences.

[146]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[147]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[148]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[149]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[150]  Thomas A M Kramer,et al.  Drug development. , 2002, MedGenMed : Medscape general medicine.

[151]  M. Tyers,et al.  Transcriptional regulation: Kamikaze activators , 2000, Current Biology.

[152]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[153]  A. Zelent,et al.  Fusion between a novel Krüppel‐like zinc finger gene and the retinoic acid receptor‐alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. , 1993, The EMBO journal.

[154]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[155]  P. Leder,et al.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[156]  Pierre Chambon,et al.  In vivo sequence requirements of the SV40 early promoter region , 1981, Nature.

[157]  K. McPherson,et al.  MORTALITY IN ORAL CONTRACEPTIVE USERS , 1981, The Lancet.

[158]  P. Gruss,et al.  Simian virus 40 tandem repeated sequences as an element of the early promoter. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[159]  J. Banerji,et al.  Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. , 1981, Cell.

[160]  Peter A. Jones,et al.  Multiple new phenotypes induced in 10T 1 2 and 3T3 cells treated with 5-azacytidine , 1979, Cell.

[161]  J. Rowley,et al.  15/17 TRANSLOCATION, A CONSISTENT CHROMOSOMAL CHANGE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1977, The Lancet.

[162]  S. Farber.  The future of the cancer chemotherapy national program. , 1960, National Cancer Institute monograph.